Hepatic complications of allogeneic hematopoietic cell transplantation

Turkish Journal of Hematology

Volumn 25, Issue 3, 2008, Pages 111-123

  Idilman, Ramazan ^a   Arat, Mutlu ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Allogeneic hematopoietic cell transplantation; Bone marrow transplantation; Hepatic complications; Liver

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BILIRUBIN; BUSULFAN; CHELATING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFEROXAMINE; FLUCONAZOLE; GLUTATHIONE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PLACEBO; RAPAMYCIN; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HEMATOLOGIC DISEASE; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; IRON OVERLOAD; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MORBIDITY; MORTALITY; MYCOSIS; ORGAN DONOR; PHLEBOTOMY; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SCLEROSING CHOLANGITIS; SEPSIS; SIDE EFFECT; SINUSOIDAL OBSTRUCTION SYNDROME; VIRUS REPLICATION; WHOLE BODY RADIATION;

EID: 53249132859     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Thomas ED, Bone marrow transplantation: a review: Semin Hematol 1999; 36: 95-103.
2. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11: 215-29.
3. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Blume K, Forman W, Appelbaum FR, editors. Thomas's Hematopoietic Cell Transplantation. Australia: Blackwell, 2004: 769-810.
4. Liatsos C, Mehta AB, Potter M, Burroughs AK. The hepatologist in the haematologists' camp: Br J Haematol 2001; 113: 567-78.
5. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results: Arch Intern Med 2002; 162:1558-66.
6. McCrudden R, Williams DB, O'Connor T, Vickers CR. Gastrointestinal, hepatic, gallbladder, pancreatic, and perianal complications. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Brenner MK, editors. Clinical Bone Marrow and Stem Cell Transplantation. United Kingdom: Cambridge University Press, 2004: 1417-53.
7. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618-28.
8. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
9. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999; 93: 1127-36.
10. Locasciulli A, Alberti A, Bandini G, Polchi P, Arcese W, Alessandrino P et al. Alogeneic bone marrow transplantation from HbsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995; 86: 3236-40.
11. Lau GKK, Lie AKW, Kwong YL, Lee CK, Hou J, Lau YL et al. A case-controlled study on the use of HBsAg-posftive donors for allogeneic hematopoietic stem cell transplantation. Blood 2000; 96: 452-8.
12. Ustun C, Idilman R, Gurman G, Ozcan M, Akyoll G, Akan H et al. Hematopoietic stern cell transplantation from non-replicative hepatitis B carriers is safe. J Hepatol 1999; 31: 202-9.
13. Locasciulli A, Nava S, Sparano P, Testa M. Infections with hepatotropic viruses in children treated with allogeneic hematopoietic bone marrow transplantation. Bone Marrow Transplant 1998; 21: S75-7.
14. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-1occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematoll 2003; 10: 451-62.
15. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-20.
16. De Leve LD, Wang XD, Huybrechts MM. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830-7.
17. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the fiver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
18. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-30.
19. Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 1980; 104: 584-8.
20. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busuffan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 82: 2723-30.
21. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
22. Jones RJ, Lee KSK, Beschomer WE, Vogel VG, Grochow, LB, Braine HG et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-83.
23. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplantation recipients. Transplantation 1995; 59: 1015-22.
24. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-8.
25. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG et al. Hepatitis C virus infection after bone marrow transplantation: a cohort study with 10 year follow-up. Hepatology 1999; 29: 1893-9.
26. Attal M, Huguet F, Rubie H. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-40.
27. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-8.
28. Essell JH, Schroeder MT, Harman GS, Halvorson RH, Lwe V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. Ann Intern Med 1998; 128: 975-81.
29. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-83.
30. Zaia J. Viral infections associated with bone marrow transplandtion. Hematol Oncol Clin North Am 1990; 4: 603-23.
31. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44-57.
32. Roberts MM, To LB, Gillis D, Mundy J, Rawling C, Ng K, Juttner CA. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-75.
33. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19; 161-72.
34. Ustun C, Koc H, Karayalcin S, Akyol G, Gurman G, Ilhan O et al. Hepatitis B Arus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 289-96.
35. Lau GKK, He M, Fong DYT, Bartholomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-9.
36. Locasciulli A, Alberti A, de Bock R, Cordonnier C, Einsele H, Engelhard D et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe. Bone Marrow Transplant 1994; 14: 833-7.
37. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EKW, Lau YL et al. Clearance of hepatitis B surface antigen after bone marrow transplantation role of adoptive immunity transfer. Hepatology 1997; 25: 1497-501.
38. Idilman R, Ustun C, Karayalcin S, Aktenel A, Turkyilmaz AR, Ozcan M et al. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant 2003; 17: 438-43.
39. Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, Brautbar C, Shouval D. Adoptive transfer of immunity to hepatitis B virus after T cell depleted allogeneic bone marrow transplantation. Hepatology 1993; 18: 246-52.
40. Nagler A, Ilan Y, Adler R, Or R, Naparstek E, Shouval D et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995; 15: 475-8.
41. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayiannis P, Griffiths PD et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339-43.
42. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
43. Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: precore/core mutations may play an important role. J Med Virol 2000; 60: 249-55.
44. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-31.
45. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 36-43.
46. Idilman R, Arai M, Soydan E, Toruner M, Soykan I, Akbulut H et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11: 141-7.
47. Chan TM, Fang GX, Tang CSO, Cheng IK, Lai KN, Ho SK Preemptive lamivudine therapy based on HBV-DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-52.
48. Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Therap 2003; 25: 3084-99.
49. Van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. Medicine 1998; 77: 246-54.
50. Akpek G. Graft-versus-host disease: an evidence-based management guideline. Turk J Hematol 2003; 20: 123-42.
51. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 10: 667-74.
52. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation. Massachusetts: Blackwell Science, 1999: 248-63.
53. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-72.
54. Sullivan KM, Agura E, Appelbaum F, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 249-58.
55. Storek J, Gooley T, Siadak M. Allogeneic peiripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 12: 4705-9.
56. Atkinson K, Horowitz MM, Gale RP, van Beldaim DW, Gluckman E, Good RA et al. Risk factors of chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-64.
57. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: a long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-17.
58. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988; 8: 463-70.
59. Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change? Leuk Lymphoma 2002; 43: 1211-20.
60. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481-6.
61. Goulis J, Leandro G, Burroughs AK. Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta analysis. Lancet 1999; 354: 1053-60.
62. Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121: 207-18.
63. Barnes D, Talenti D, Cammell G, Goormastic M, Farquhar L, Henderson M et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 1997; 26: 853-7.
64. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-vemus-host disease of the liver. Ann Intern Med 1992; 116: 624-9.
65. Arat M, Idilman R, Soydan E, Soykan I, Erden E, Karayalcin S et al. Ursodeoxycholic acid treatment in isolated chronic graft-versus-host disease of the liver. Clin Transplant, in press.
66. McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P et al. Iron overload and liver dysfunction after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 63-6.
67. Tavill AS, Bacon B. Hemochromatosis and the iron overload syndromes. In: Zakim D, Boyer TD, editors. Hepatology. A Textbook of Liver Disease. Philadelphia, Pennsylvania: Saunders, 2003: 1289-316.
68. Trauner M, Nathanson MH, Rydberg SA, Koeppel TA, Gartung C, Sessa WC et al. Endatoxin impairs biliary glutathione and HCO3 excretion and blocks the choleratic effect of nitric oxide in rat liver, Hepatology 1997; 25: 1184-91.
69. Ericzon BG, Eusufzai S, Soderdahl G, Duraj F, Einarsson K, Angelin B. Secretion and composition of bile after human liver transplantation: studies on effects of cyclosporine and tacrolimus. Transplantation 1997; 63: 74-80.
70. Bashir R, Lipman T. Hepatobiliary toxicity of total parenteral nutrition in adults, Gastroenterol Clin North Am 1995; 24: 1003-25.
71. Briones Er, Iber FL. Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. J Am Coll Nutr 1995; 14: 219-28.
72. Messing B, Bodes C, Kunstlinger F, Bernier JJ. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology 1983; 84: 1012-9.
73. Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93: 3259-66.
74. Me SY, Au WY, Ng IOL, Lie AKW, Leung AYH, Liang RHS et al. Role of liver biopsy in the management of liver dysfunction after hematopoietic stem cell transplantation in a hepatitis B virus prevalent patient population. Transplantation 2003; 76: 169-76.
75. McAfee JH, Keeffe EB, Lee RG, Rosch J. Transjugular liver biopsy. Hepatology 1992; 15: 726-32.